scholarly journals Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study

2015 ◽  
pp. 197 ◽  
Author(s):  
Jihyung Hong ◽  
Diego Novick ◽  
William Montgomery ◽  
Héctor Dueñas ◽  
Magdy Gado ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Observational Study ◽  
Depressive Disorder ◽  
Real World ◽  
Prospective Observational Study ◽  
Major Depressive ◽  
Real World Evidence

Factors associated with frovatriptan response in patients with migraine: A prospective, observational study

Cephalalgia ◽  
2015 ◽  
Vol 36 (5) ◽  
pp. 493-498 ◽  
Author(s):  
Jong-Geun Seo ◽  
Sung-Pa Park
Keyword(s):  
Major Depressive Disorder ◽  
Risk Factor ◽  
Observational Study ◽  
Confidence Interval ◽  
Depressive Disorder ◽  
Odds Ratio ◽  
Prospective Observational Study ◽  
Major Depressive ◽  
Factors Associated ◽  
Headache Clinic

Background Almost one-third of patients with migraine do not adequately respond to triptans. We examined factors contributing to frovatriptan response in patients with migraine. Methods We enrolled new patients with migraine who consecutively visited our headache clinic. Eligible patients were instructed to take 2.5 mg of frovatriptan as soon as possible after migraine attack. The responsiveness was determined by whether headache was relieved or absent within 4 hours after the intake of frovatriptan. We assessed frovatriptan to be efficacious when headache responded to its administration in at least one of two successive migraine attacks and inefficacious when headache was not relieved in either attack. We included demographic, clinical and psychiatric variables in the analysis of factors associated with frovatriptan response. Results Of 128 eligible patients, 28 (21.9%) experienced frovatriptan inefficacy. In 24 patients with current major depressive disorder, 12 (50.0%) had frovatriptan inefficacy. Only current major depressive disorder was identified as a risk factor for inefficacy (odds ratio = 5.500, 95% confidence interval 2.103–14.382, p = 0.001). Conclusions Depression may be a risk factor of frovatriptan inefficacy in patients with migraine, even though half of patients with major depressive disorder respond to frovatriptan.

Major depressive disorder with subthreshold hypomanic (mixed) features: A real-world assessment of treatment patterns and economic burden

2017 ◽  
Vol 210 ◽  
pp. 332-337 ◽  
Author(s):  
Roger S. McIntyre ◽  
Daisy Ng-Mak ◽  
Chien-Chia Chuang ◽  
Rachel Halpern ◽  
Pankaj A. Patel ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Real World ◽  
Economic Burden ◽  
Treatment Patterns ◽  
Major Depressive ◽  
Mixed Features

Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice

CNS Spectrums ◽  
2016 ◽  
Vol 22 (4) ◽  
pp. 342-347 ◽  
Author(s):  
Domenico De Berardis ◽  
Michele Fornaro ◽  
Laura Orsolini ◽  
Felice Iasevoli ◽  
Carmine Tomasetti ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Clinical Practice ◽  
Depressive Symptoms ◽  
Depressive Disorder ◽  
Real World ◽  
Level Variation ◽  
C Reactive Protein ◽  
Major Depressive ◽  
Everyday Clinical Practice ◽  
Reactive Protein

ObjectiveAgomelatine is a newer antidepressant but, to date, no studies have been carried out investigating its effects on C-reactive protein (CRP) levels in major depressive disorder (MDD) before and after treatment. The present study aimed (i) to investigate the effects of agomelatine treatment on CRP levels in a sample of patients with MDD and (ii) to investigate if CRP variations were correlated with clinical improvement in such patients.Methods30 adult outpatients (12 males, 18 females) with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of MDD were recruited in “real-world,” everyday clinical practice and treated with a flexible dose of agomelatine for 12 weeks. The Hamilton Rating Scale for Depression (HAM-D) and the Snaith-Hamilton Pleasure Scale (SHAPS) were used to evaluate depressive symptoms and anhedonia, respectively. Moreover, serum CRP was measured at baseline and after 12 weeks of treatment.ResultsAgomelatine was effective in the treatment of MDD, with a significant reduction in HAM-D and SHAPS scores from baseline to endpoint. CRP levels were reduced in the whole sample, with remitters showing a significant difference in CRP levels after 12 weeks of agomelatine. A multivariate stepwise linear regression analysis showed that higher CRP level variation was associated with higher baseline HAM-D scores, controlling for age, gender, smoking, BMI, and agomelatine dose.ConclusionsAgomelatine’s antidepressant properties were associated with a reduction in circulating CRP levels in MDD patients who achieved remission after 12 weeks of treatment. Moreover, more prominent CRP level variation was associated with more severe depressive symptoms at baseline.

Sign in / Sign up

Export Citation Format

Share Document